N/A
Completed N=13
Metaplasticity Experimental Design and Comparison of Motor Outcome Measure Sensitivity to Change
Healthy
Source: ClinicalTrials.gov NCT03304262 ↗
Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Aug 2023
Primary outcomePrimary: Percent Change in MEP Amplitude — 1.19; 1.06; 1.38 Percent Change
Summary
The overall objective is to validate the methodology of a metaplasticity experimental design by assessing change in motor excitability after administration of priming transcranial direct current stimulation (tDCS) followed by repetitive transcranial magnetic stimulation (rTMS) in healthy human participants.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in MEP Amplitude |
1.19; 1.06; 1.38 | — |
| SECONDARY Cortical Silent Period |
1.02; 1.01; 0.99 | — |
| SECONDARY Simple Reaction Time |
1.01; 1.02; 1.02 | — |
Eligibility Criteria
Inclusion Criteria
- Must be at least 18 years of age (all genders, races, ethnicity)
- Must have no current psychiatric or neurologic issues
- Must not have any conditions listed in exclusion criteria
- Must be fluent in English
Exclusion Criteria
- History of major psychiatric illness
- Actively using neuropsychoactive medication
- Legal or mental incompetency
- Substance use disorder, abuse or dependence, with active use within the last three months
- Significant medical or neurological illness
- Prior neurosurgical illness
- Prior neurosurgical procedure
- History of seizure
- History of ECT or TMS treatment within the past there months
- Presence of a pacemaker, implanted medical pump or device, metal plate, or metal object in skull or eye (including shunts, dental implants, facial tattoos with metallic ink)
- Pregnant women
Data sourced from ClinicalTrials.gov (NCT03304262). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.